One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

BACKGROUND: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase III randomized controlled trial. We present op...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrezenmeier, Hubert, Kulasekararaj, Austin, Mitchell, Lindsay, Sicre de Fontbrune, Flore, Devos, Timothy, Okamoto, Shinichiro, Wells, Richard, Rottinghaus, Scott T., Liu, Peng, Ortiz, Stephan, Lee, Jong Wook, Socié, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592174/
https://www.ncbi.nlm.nih.gov/pubmed/33178408
http://dx.doi.org/10.1177/2040620720966137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592174/
https://www.ncbi.nlm.nih.gov/pubmed/33178408
http://dx.doi.org/10.1177/2040620720966137

Ejemplares similares